Trending

Top stories

CF patients furious as Vertex turns back on NICE

CF patients furious as Vertex turns back on NICE

Patients in England could be denied access to drug

X

CF patients furious as Vertex turns back on NICE

https://pharmaphorum.com/news/cf-patients-furious-as-vertex-turns-back-on-nice/

Millions of health records exposed to public in Mexico

Millions of health records exposed to public in Mexico

A German cyber security enthusiast says he discovered an unprotected online healthcare database and gained access to 2.3

X

Millions of health records exposed to public in Mexico

https://pharmaphorum.com/news/health-records-publically-exposed/

Lundbeck brings third Parkinson’s drug into clinic

Lundbeck brings third Parkinson’s drug into clinic

Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody

X

Lundbeck brings third Parkinson’s drug into clinic

https://pharmaphorum.com/news/lundbeck-brings-third-parkinsons-drug-into-clinic/

Pharma braces for ‘hard Brexit’ despite new guidance

Pharma braces for ‘hard Brexit’ despite new guidance

Trade body prepares for the worst-case scenario

X

Pharma braces for ‘hard Brexit’ despite new guidance

https://pharmaphorum.com/news/pharma-braces-for-hard-brexit-despite-new-guidance/

Neurofibromatosis treatment granted orphan status by EMA

Neurofibromatosis treatment granted orphan status by EMA

AstraZeneca and Merck & Co. announced the European Medicines Agency (EMA) has granted orphan designation to their codeveloped

X

Neurofibromatosis treatment granted orphan status by EMA

https://pharmaphorum.com/news/nf1-treatment-granted-orphan-status-ema/

NHS saved £324 million by switching to biosimilars and generics

NHS saved £324 million by switching to biosimilars and generics

The UK’s national healthcare provider saved £324 million by switching its patients to “better value” biosimilar and generic

X

NHS saved £324 million by switching to biosimilars and generics

https://pharmaphorum.com/news/nhs-saved-millions-switching-biosimilars/

Sanofi stockpiles drugs in case of no-deal Brexit

Sanofi stockpiles drugs in case of no-deal Brexit

Fears of border delays and complications in a post-Brexit UK have led to the French pharmaceutical company increasing

X

Sanofi stockpiles drugs in case of no-deal Brexit

https://pharmaphorum.com/news/sanofi-stockpiles-drugs-case-deal-brexit/

Breakthrough migraine prevention treatment approved in Europe

Breakthrough migraine prevention treatment approved in Europe

Novartis’ Aimovig (erenumab) has been approved by the European Medicines Agency (EMA) making it first self-administered, monthly migraine

X

Breakthrough migraine prevention treatment approved in Europe

https://pharmaphorum.com/news/breakthrough-migraine-prevention-treatment-approved-in-europe/

Roche’s MS drug Ocrevus earns blockbuster status a year after launch

Roche’s MS drug Ocrevus earns blockbuster status a year after launch

Roche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster status just one year after it was launched.

X

Roche’s MS drug Ocrevus earns blockbuster status a year after launch

https://pharmaphorum.com/news/roche-ms-ocrevus-blockbuster/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com